News

Pfizer's sickle-cell treatment efforts falter

Pfizer's sickle-cell treatment efforts falter as drug fails study
In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal in a late-stage trial for patients aged 16 and older.
Pfizer’s $5.4B GBT Bet Disappoints Again as Sickle Cell Therapy Fails in Phase III
Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain episodes in patients with sickle cell disease over the 48-week treatment period.
Pfizer’s SCD drug fails ph. 3 study in latest blow to Global Blood Therapeutics' legacy
Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those trials, which was examining the safety and efficacy of inclacumab in reducing vaso-occlusive crisis (VOCs) experienced by patients with SCD, back in March 2024, citing “slow recruitment” of patients.
Pfizer’s Sickle Cell Treatment Fails Phase 3 Study
Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains committed to future treatments.
Pfizer’s (PFE) Sickle Cell Drug Fails to Meet Its Main Goal
Drugmaker Pfizer ($PFE) recently shared disappointing news about its experimental drug for sickle cell disease, inclacumab. In a late-stage
Pfizer fails in late-stage trial for sickle cell disease therapy
Pfizer (NYSE:PFE) announced Friday that a late-stage clinical trial for inclacumab, its experimental therapy for the blood disorder sickle cell disease, did not meet the main goal, marking the latest setback for its SCD portfolio.
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.
Pfizer's sickle cell drug fails main goal in late-stage trial
Pfizer said on Friday that its experimental sickle cell disease drug failed to meet the main goal in a late stage trial in patients 16 years of age and older.
Pfizer experimental sickle cell drug fails phase 3 trial
Woman in US for nearly 3 decades arrested by ICE after traffic stop Hiker who died after being bitten by venomous snake in Tennessee made fatal mistake, officials believe Here’s Why You May See Turquoise Arches at McDonald’s Queen moved to tears as veteran comforts King over cancer diagnosis Water levels plunge at Lake Powell.
Yahoo Finance10mon

Pfizer withdraws sickle cell disease treatment on risk of complication ...

Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022. Pfizer is also discontinuing all studies and access programs related to the ...
GEN6y

Pfizer, GlycoMimetics Phase III Drug Fails Phase III Trial for Sickle ...

According to GlycoMimetics’ Form 10-K for 2018, Pfizer has paid GlycoMimetics $22.5 million upfront, and $35 million tied to the dosing of the first patient in RESET, consisting of a $15 million ...
Reuters10mon

Pfizer withdraws sickle-cell disease treatment | Reuters

Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing ...
STAT9h

Pharmalittle: We’re reading about a setback for Pfizer, a boost for Novo Nordisk, and much more

An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and ...